Coagulation factor ix (recombinant), fc fusion protein - Biologic Drug Details

Summary for coagulation factor ix (recombinant), fc fusion protein

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for coagulation factor ix (recombinant), fc fusion protein

Recent Clinical Trials for coagulation factor ix (recombinant), fc fusion protein

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Syneos Health	Phase 3
Jiangsu Gensciences lnc.	Phase 2
Mansoura University	N/A

See all coagulation factor ix (recombinant), fc fusion protein clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for coagulation factor ix (recombinant), fc fusion protein Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for coagulation factor ix (recombinant), fc fusion protein Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2033-07-03	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2034-03-14	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2038-07-25	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2024-05-06	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for coagulation factor ix (recombinant), fc fusion protein Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for coagulation factor ix (recombinant), fc fusion protein

Country	Patent Number	Estimated Expiration
Australia	2019202348
Brazil	112015000025
Singapore	10201707600X
Taiwan	I656073
Taiwan	202222336
Hong Kong	1220619
Taiwan	201524514

Market Dynamics and Financial Trajectory for Coagulation Factor IX (Recombinant) Fc Fusion Protein

Last updated: July 30, 2025

Introduction

The biologic landscape continues to evolve rapidly, driven by innovations in recombinant protein engineering and targeted therapeutics. Among these, coagulation factor IX (rFIX) Fc fusion proteins stand out as a transformative advancement in hemophilia B management. Their market trajectory hinges on a confluence of clinical innovation, regulatory support, competitive pressures, and investment trends. This article examines the key market dynamics and financial prospects for recombinant factor IX Fc fusion proteins, emphasizing their strategic positioning within the hemophilia treatment paradigm.

---

Understanding the Biologic: Coagulation Factor IX Fc Fusion Protein

Recombinant coagulation factor IX Fc fusion protein (e.g., eftrenonacog alfa, marketed as Esperoct by Novo Nordisk) is engineered to extend the half-life of standard rFIX molecules. This is achieved by fusing factor IX with the Fc domain of immunoglobulin G1 (IgG1), exploiting the body's natural recycling pathways. The result is a longer duration of action, which facilitates less frequent dosing, enhances patient adherence, and potentially improves clinical outcomes compared to conventional therapies.

---

Market Drivers

1. Growing Hemophilia B Prevalence and Diagnostic Advances

The global prevalence of hemophilia B (hemophilia B deficiency) is approximately 1 in 25,000 male births, translating into an estimated 15,000 to 20,000 patients in the United States alone [1]. Improved diagnostics, heightened awareness, and increased screening contribute to earlier and more accurate identification, expanding the diagnosed population segment. As therapies become more patient-friendly, more individuals seek treatment, bolstering demand.

2. Therapeutic Advantages of Fc Fusion Proteins

The primary advantage of Fc fusion proteins lies in their extended half-life—up to five times longer than standard rFIX—enabling weekly or biweekly administration versus multiple weekly infusions. This shorter infusion schedule enhances patient quality of life, reduces treatment burden, and improves adherence, all critical factors for long-term disease management.

3. Regulatory Landscape and Market Approvals

Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved Fc fusion proteins for hemophilia B, establishing clinical efficacy and safety benchmarks. Novo Nordisk's Esperoct received EMA approval in 2019 and FDA approval concurrently [2], paving the way for market penetration in major territories.

4. Growing Adoption and Clinical Evidence

Real-world evidence and clinical trial data demonstrate comparable or superior efficacy with reduced infusion frequency. Increasing clinical confidence facilitates market penetration among physicians, especially as registry data confirms safety and efficacy profiles.

5. Competitive Dynamics

The market for hemophilia B therapies includes standard recombinant FIX, plasma-derived products, and newer gene therapies. Fc fusion proteins compete primarily on convenience, safety, and long-term cost-effectiveness. Although gene therapy promises potentially curative outcomes, it remains in early adoption stages for many markets, leaving recombinant Fc fusion proteins as a mainstay treatment.

---

Market Challenges

1. Gene Therapy Competition and Market Uncertainty

Gene therapies, such as BioMarin’s valoctocogene roxaparvovec and Pfizer’s investigational programs, propose durable or even permanent correction of coagulation deficiency [3]. While still facing regulatory, cost, and safety hurdles, their potential to reshape treatment paradigms is significant, possibly constraining market growth of biologics.

2. High Cost and Reimbursement Barriers

Biologic therapies, especially advanced recombinant proteins, entail substantial costs. Reimbursement constraints and pricing negotiations impact market access, particularly in healthcare systems with budgetary pressures [4].

3. Biologic Design Innovations

Emerging platforms, such as PEGylation and other half-life extension technologies, offer alternative approaches to Fc fusion. Competition among biotech firms driving innovation may fragment market share.

4. Market Penetration in Emerging Economies

Access limitations, regulatory hurdles, and pricing policies slow expansion into low- and middle-income regions, restricting overall market volume.

---

Financial Trajectory and Investment Outlook

1. Revenue Projections and Market Size

The global hemophilia B therapeutics market is projected to reach USD 2.4 billion by 2027, growing at a compound annual growth rate (CAGR) of approximately 7-9% [5]. Fc fusion proteins are expected to constitute a significant segment owing to their clinical advantages.

2. Key Market Players and their Strategies

• Novo Nordisk: Industry leadership with Esperoct leverages a robust pipeline and global marketing network. They pursue strategic collaborations, including manufacturing expansion and post-approval clinical trials.

• Takeda and BioMarin: Compete with their respective products and pipeline innovations. Their focus remains on differentiated glycoengineering and gene therapies.

• Small and Emerging Biotechs: Innovate with alternative half-life extension technologies, positioning for niche markets or specific patient subsets.

3. R&D Investment Trends

Substantial R&D funding is directed toward next-generation biologics: bispecific antibodies, gene editing, and improved Fc fusion constructs. Investors view Fc fusion biologics as mature, predictable assets with manageable development risk, underpinning stable revenue streams.

4. Pricing and Reimbursement Dynamics

Pricing strategies are increasingly influenced by health technology assessments (HTAs) and value-based agreements. The extended dosing frequency reduces overall treatment costs per patient and appeals to payers, positively influencing revenue potential.

5. Impact of Regulatory and Policy Environment

Regulatory approval pathways favor biologic innovation but also impose rigorous safety and efficacy requirements. Policy shifts towards value-based care may drive manufacturers to optimize dosing regimens and demonstrate long-term cost savings, supporting premium pricing models.

---

Market Outlook and Growth Potential

The forecast indicates sustained growth driven by demographic trends, improved patient management, and clinician preference for convenient, long-acting therapies. The long-term financial trajectory hinges upon successful commercialization, reimbursement negotiations, and the advent of competing modalities like gene therapy. The biologic’s revenue is expected to peak within the next five years, followed by stabilization or decline as new entrants and therapeutic concepts mature.

---

Regulatory and Commercial Opportunities

Manufacturers can capitalize on the favorable regulatory landscape by expanding clinical indications, such as prophylaxis in pediatric populations, and pursuing indications for other bleeding disorders. Commercial strategies should focus on expanding access in emerging markets and integrating real-world evidence into payer negotiations.

---

Key Takeaways

• Growth Drivers: Enhanced diagnostics, patient-centric therapy advantages, and regulatory approvals fuel the expanding market for Fc fusion rFIX products.
• Competitive Landscape: Market shares are consolidating among established biologics, while innovation continues with alternative half-life extension technologies.
• Financial Outlook: Strong revenue prospects exist, supported by high patient retention, improved adherence, and premium pricing based on therapeutic benefits.
• Market Challenges: Gene therapy competition, reimbursement constraints, and market access barriers threaten sustained growth.
• Strategic Focus: Manufacturers should prioritize pipeline innovation, global expansion, and value demonstration to maximize long-term profitability.

---

FAQs

1. How does coagulation factor IX Fc fusion protein differ from traditional therapies?
Fc fusion extends the half-life of factor IX, reducing infusion frequency from multiple weekly doses to once weekly or biweekly, thereby improving patient adherence and quality of life.

2. What are the key factors influencing market adoption of Fc fusion proteins?
Clinical efficacy, safety profile, cost-effectiveness, regulatory approvals, physician familiarity, and payer reimbursement policies are critical determinants of market adoption.

3. What does the competitive landscape look like for coagulation factor IX biologics?
It comprises established products like Esperoct, newer biologics, gene therapies in late-stage development, and emerging platforms offering alternative half-life extension strategies.

4. How might gene therapy impact the market for Fc fusion proteins?
Gene therapy offers the potential for a one-time, curative approach, which could diminish demand for biologic therapies over time, especially if long-term safety and efficacy are confirmed.

5. What strategies should manufacturers adopt to secure market share?
Focusing on pipeline innovation, expanding indications, improving manufacturing efficiency, demonstrating long-term value, and entering emerging markets can enhance market positioning.

---

References

[1] World Federation of Hemophilia. Hemophilia Statistics. 2022.
[2] EMA. Estephrect (Esperoct) Summary of Product Characteristics. 2019.
[3] BioPharm Insight. Hemophilia gene therapy pipeline analysis. 2022.
[4] IQVIA Institute. The Global Use of Medicines in Hemophilia. 2021.
[5] MarketsandMarkets. Hemophilia Therapeutics Market Forecast. 2022.